Live Analyst Rating Changes 42254 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrea Newkirk
GS

Andrea Newkirk

Goldman Sachs
Wall Street Analyst
★★★☆☆
#2113
on 13Foresight · ranked by our own returns
41%
Success Rate
+34.0%
Average Return
12 of 29 calls profitable · +55.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 41% of Andrea Newkirk's ratings turned a profit when each position was held for 1 year — averaging +34.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

11 Buy 10 Hold 5 Sell
Andrea's Stock Coverage 18 ratings · 2026-10-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SGMT
Sagimet Biosciences, Inc. Class A
 Sep 30, 2026 SELL Strong Buy
+272.8% avg upside
17 analysts
$7.00
7.16% Downside
 +23.6% ·
KOD
Kodiak Sciences
 Sep 29, 2026 HOLD Strong Buy
-3.4% avg upside
12 analysts
$103.00
26.96% Upside
 -11.0% ·
UTHR
United Therapeutics
 Sep 24, 2026 SELL Buy
-16.3% avg upside
27 analysts
$321.00
40.64% Downside
 -14.7% ·
MGTX
Meiragtx Holdings
 Sep 24, 2026 HOLD Strong Buy
+165.6% avg upside
14 analysts
$16.00
70.13% Upside
 -14.8% ·
RVMD
Revolution Medicines
 Sep 24, 2026 BUY Strong Buy
+7.2% avg upside
35 analysts
$267.00
37.91% Upside
 -4.3% ·
TARS
Tarsus Pharmaceuticals
 Sep 24, 2026 BUY Strong Buy
+13.3% avg upside
17 analysts
$116.00
60.52% Upside
 -6.8% ·
ABCL
AbCellera Biologics
 Sep 24, 2026 HOLD Strong Buy
+27.6% avg upside
17 analysts
$13.00
5.06% Upside
 -2.2% ·
ALKS
Alkermes
 Sep 24, 2026 HOLD Strong Buy
+11.1% avg upside
34 analysts
$50.00
27.99% Upside
 -1.3% ·
ARWR
Arrowhead Pharmaceuticals
 Sep 24, 2026 HOLD Strong Buy
+26.9% avg upside
28 analysts
$74.00
26.82% Upside
 -8.1% ·
INSM
Insmed
 Sep 24, 2026 BUY Strong Buy
+73.1% avg upside
37 analysts
$188.00
92.29% Upside
 -19.0% ·
JAZZ
Jazz Pharmaceuticals
 Sep 24, 2026 BUY Strong Buy
+18.6% avg upside
36 analysts
$337.00
60.72% Upside
 -11.3% ·
MDGL
Madrigal Pharmaceuticals
 Sep 24, 2026 BUY Strong Buy
+12.3% avg upside
34 analysts
$704.00
53.12% Upside
 -11.9% ·
IOVA
Iovance Biotherapeutics
 Sep 24, 2026 BUY Strong Buy
+9.5% avg upside
26 analysts
$15.00
5.46% Upside
 +34.3% ·
KRYS
Krystal Biotech
 Sep 24, 2026 BUY Strong Buy
-14.8% avg upside
20 analysts
$441.00
33.32% Upside
 -6.9% ·
SDGR
Schrodinger
 Nov 07, 2025 HOLD Strong Buy
+10.9% avg upside
16 analysts
$21.00
16.09% Downside
 +42.0% ·
VOR
Vor Biopharma
 Dec 19, 2024 HOLD Strong Buy
+128.4% avg upside
17 analysts
 — -30.0% ·
DTIL
Precision BioSciences
 Dec 19, 2024 HOLD Strong Buy
+286.8% avg upside
12 analysts
 — -2.4% ·
RLMD
Relmada Therapeutics
 Dec 04, 2024 HOLD Buy
+310.7% avg upside
15 analysts
 — +534.9% ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrea Newkirk — Frequently Asked Questions
How accurate are Andrea Newkirk's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Andrea's ratings were profitable over a one-year hold, with an average return of +34.0% per rating, or +55.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andrea ranked on 13Foresight?
Andrea Newkirk is currently ranked #2113 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrea cover?
Andrea most recently has ratings on SGMT, KOD, UTHR, MGTX, RVMD, TARS, ABCL, ALKS, ARWR, INSM, JAZZ, MDGL and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.